Nonprofit buys experimental cancer drug to maintain patient access
-
By
-
Lauren Chan
-
June 11, 2026
-
Clinical Scorecard: Nonprofit Organization Acquires Investigational Cancer Medication to Ensure Patient Availability
At a Glance
| Category | Detail |
|---|
| Condition | Rare form of blood cancer in children |
| Key Mechanisms | Antibody-drug-conjugate targeting folate receptor (FOLR1) |
| Target Population | Children with rare blood cancers, particularly acute myeloid leukemia |
| Care Setting | Compassionate-use program managed by Blood Cancer United |
Key Highlights
- Blood Cancer United acquires remaining supplies of Luvelta for compassionate use.
- Luvelta can serve as a bridge to stem cell transplantation for specific patients.
- The drug was previously discontinued by Sutro Biopharma due to funding priorities.
- Approximately 20 new patients may use Luvelta annually.
- Current supply of Luvelta has an expiry date of 2028.
Guideline-Based Recommendations
Diagnosis
- Identify children with rare forms of blood cancer eligible for Luvelta.
Management
- Administer Luvelta as part of a compassionate-use program.
Monitoring & Follow-up
- Evaluate patient response and potential side effects of Luvelta.
Risks
- Consider the economic realities affecting drug availability for rare diseases.
Patient & Prescribing Data
Children diagnosed with rare blood cancers, particularly acute myeloid leukemia.
Luvelta has shown potential in treating pediatric patients, with a focus on compassionate use.
Clinical Best Practices
- Facilitate access to investigational drugs through nonprofit initiatives.
- Prioritize pediatric applications in drug development and trials.
- Engage in stability testing for potential shelf-life extension of medications.
Related Resources & Content
